Bioadaptives Stock Cash And Equivalents
| BDPT Stock | USD 0.10 0.01 9.09% |
BioAdaptives fundamentals help investors to digest information that contributes to BioAdaptives' financial success or failures. It also enables traders to predict the movement of BioAdaptives Pink Sheet. The fundamental analysis module provides a way to measure BioAdaptives' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioAdaptives pink sheet.
BioAdaptives |
BioAdaptives Company Cash And Equivalents Analysis
BioAdaptives' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current BioAdaptives Cash And Equivalents | 49.58 K |
Most of BioAdaptives' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioAdaptives is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, BioAdaptives has 49.58 K in Cash And Equivalents. This is 100.0% lower than that of the Consumer Defensive sector and 99.99% lower than that of the Packaged Foods industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.
BioAdaptives Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioAdaptives' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioAdaptives could also be used in its relative valuation, which is a method of valuing BioAdaptives by comparing valuation metrics of similar companies.BioAdaptives is currently under evaluation in cash and equivalents category among its peers.
BioAdaptives Fundamentals
| Return On Asset | -3.43 | |||
| Operating Margin | (33.58) % | |||
| Current Valuation | 544.74 K | |||
| Shares Outstanding | 160.49 M | |||
| Shares Owned By Insiders | 7.39 % | |||
| Price To Earning | (14.28) X | |||
| Price To Sales | 7.53 X | |||
| Revenue | 19.78 K | |||
| Gross Profit | 10.11 K | |||
| EBITDA | (643.76 K) | |||
| Net Income | (1.05 M) | |||
| Cash And Equivalents | 49.58 K | |||
| Total Debt | 450.26 K | |||
| Current Ratio | 0.04 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (158.65 K) | |||
| Earnings Per Share | (0.02) X | |||
| Beta | -0.29 | |||
| Market Capitalization | 144.44 K | |||
| Total Asset | 148.59 K | |||
| Retained Earnings | (2.96 M) | |||
| Working Capital | (160 K) | |||
| Current Asset | 156 K | |||
| Current Liabilities | 316 K | |||
| Z Score | -41.0 | |||
| Net Asset | 148.59 K |
About BioAdaptives Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioAdaptives's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAdaptives using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioAdaptives based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BioAdaptives Pink Sheet Analysis
When running BioAdaptives' price analysis, check to measure BioAdaptives' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAdaptives is operating at the current time. Most of BioAdaptives' value examination focuses on studying past and present price action to predict the probability of BioAdaptives' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAdaptives' price. Additionally, you may evaluate how the addition of BioAdaptives to your portfolios can decrease your overall portfolio volatility.